Earlier quoted context omitted.
> This is an unbalanced study. As such, it doesn't tell you anything about the ability to differentiate between the three populations. Complete Nonsense > That is not enough to be able to adequately know range of measurable values in the population of patients w/o cancer. True. But it is a promising initial signal that the distribution of non cancerous folks is probably very different from the invasive cancer folks.…
Look, you obviously have your opinions here. I'm not sure just saying "Complete nonsense" at things is really all that helpful. What I said ( "it doesn't tell you anything about the ability to differentiate between the three populations" ) is quite correct. This study shows that there is a difference between the groups of samples tested with their HER2 test strip, with a one-way p-value of ~0.002. I'm not convinced t…
You claimed this was the implication of an unbalanced study. I’m sorry but that is a complete non sequitur. It is nonsense. Most of everything else I disagree with but isn’t nonsense.
> I'm not sure what they are trying to claim in there paper... are they trying to say that they can diagnose breast cancer (which would requires many more biomarkers), or are they trying to say that they can differentiate between HER2+ and HER2- cancers (which would be more appropriate for a HER2 test).
They are simply showing different distributions of tests for different populations and observing that, foremost, the invasive cancer ones have a significantly different distribution; and that it’s shows promise as a test for the future.